Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9353160
APP PUB NO 20120244189A1
SERIAL NO

13384234

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GLAXOSMITHKLINE BIOLOGICALS S A1330 RIXENSART BRUSSELS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dequesne, Guy Rixensart, BE 10 53
Foster, Timothy Dublin, IE 11 71
Geoghegan, Joan Dublin, IE 4 22
Higgins, Judy Dublin, IE 4 22
Josefsson, Elisabet Göteborg, SE 9 87
Tarkowski, Andrej Göteborg, SE 8 50

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 30, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00